Cara Therapeutics (CARA) 10-K2021 FY Annual report

Filed: 1 Mar 22, 4:13pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: acetate, acquiree, Adbry, Advisor, algorithm, Allergy, Antitrust, argued, Asthma, brachioradial, cap, cardiovascular, CEO, Cibinqo, Colorado, Consortium, consummated, conversion, crime, CSL, culminating, cybersecurity, Davita, decree, dedicate, detain, dismissed, eighteen, fatal, feature, FIFO, foregone, forgo, freight, Galderma, hereditary, HSR, hypertension, Iceland, ID, ill, Immunology, impending, insight, instructed, ITT, largest, leader, leaving, Liechtenstein, lymphoproliferative, manifestation, Maruisihi, maximize, mission, mortality, motion, NDD, neuralgia, neurosensory, Norway, obsolete, Opzelura, overhead, paradigm, PCI, persisted, PharmD, PhD, phenotype, Polypeptide, poor, PPL, precisely, predominantly, pregnancy, presence, prioritize, proliferation, readout, Rinvoq, robustly, routinely, Russian, ruxolitinib, seize, sense, sensing, sequester, Shiratori, shut, skilled, spectrum, speculation, split, subcategory, sublicensee, Switzerland, syndrome, topline, transform, unaddressed, uncommon, underway, unique, unmarketable, unsuccessfully, urge, verified, vigorously, Virginia, visceral, waiting, wearisome

Removed: abandoned, accelerated, Anaesthesiology, analgesic, analyst, anticipation, approvability, aprepitant, article, assured, AUC, avoidance, background, BBA, blind, Brazilian, Cadillac, calculate, carryback, cholestatic, clarify, clarifying, classification, commerce, communicate, compensate, computing, concomitant, conditionally, confusion, conjunction, crossover, CSA, Curve, DEA, debilitating, deduction, destroy, dexamethasone, differentiated, discretely, dispensing, distinguish, district, dopamine, driven, dyspepsia, Emax, emerging, endocrinologic, equally, exercising, exhibited, explore, explored, exportation, faith, feasibility, Fenner, fifteen, filled, flat, flatulence, forego, formal, fourth, furnished, generalized, grantor, guideline, HAL, haloperidol, handle, headache, highest, historically, Hodgkin, hour, hrs, hyperthyroidism, idiopathic, IDMC, illicit, imbalance, impressed, impressive, IMS, inappropriately, inducing, input, insignificant, interact, intervention, Judge, Kagaku, Kenkyusho, line, location, lymphoma, Lynch, malignancy, mandated, marginal, marking, matched, medicinal, Merrill, metabolized, metoclopramide, mirror, mmHg, modulation, multifactorial, multimodal, newly, nominal, numerical, object, observe, offshore, ondansetron, opposition, overstatement, oxygen, package, participant, patch, path, pentazocine, percent, persuade, Pierce, PK, polycythemia, potent, PPS, preclude, procurement, qualification, quota, recommended, relocating, remeasure, remeasured, rental, repatriated, repeal, repeated, replace, resolving, revoke, ruled, rulemaking, Russia, SAB, Sanwa, saturation, schedule, scheduling, scopolamine, shortened, Smith, suggest, surgery, thousand, threshold, top, traditional, training, Transitional, Unaudited, understood, VAS, vera, yielded

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated CARA transcripts

CARA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

(1)

Registration Statement (Form S-3ASR No. 333-233666) of Cara Therapeutics, Inc.

(2)

Registration Statement (Form S-3 No. 333-230333) of Cara Therapeutics, Inc.

(3)

Registration Statement (Form S-8 No. 333-253714) of Cara Therapeutics, Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics, Inc.

(4)

Registration Statement (Form S-8 No. 333-236728) of Cara Therapeutics, Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics, Inc.

(5)

Registration Statement (Form S-8 No. 333-234800) of Cara Therapeutics, Inc., pertaining to the Cara Therapeutics, Inc. 2019 Inducement Plan

(6)

Registration Statement (Form S-8 No. 333-230335) of Cara Therapeutics, Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics, Inc.

(7)

Registration Statement (Form S-8 No. 333-223726) of Cara Therapeutics, Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics, Inc.

(8)

Registration Statement (Form S-8 No. 333-216606) of Cara Therapeutics, Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics, Inc.

(9)

Registration Statement (Form S-8 No. 333-210096) of Cara Therapeutics, Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics, Inc.

(10)

Registration Statement (Form S-8 No. 333-203057) of Cara Therapeutics, Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics, Inc., and

(11)

Registration Statement (Form S-8 No. 333-193905) pertaining to the 2004 Stock Incentive Plan, as amended, and 2014 Equity Incentive Plan.

of our reports dated March 1, 2022, with respect to the financial statements of Cara Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Cara Therapeutics, Inc. included in this Annual Report (Form 10-K) of Cara Therapeutics, Inc., for the year ended December 31, 2021.

/s/ Ernst & Young LLP

Stamford, Connecticut

March 1, 2022